Mylan signs U.S. license deal on Humira with AbbVie
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid/File Photo/ (Reuters) - AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the competition. The deal is in line with AbbVie's strategy to fend off rivals of the world's best-selling prescription drug until 2023, giving the company more time to bolster ...
Click
To Read Full Article